{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/205889","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01384734","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"true","masked_caregiver":"true","masked_investigator":"true","masked_subject":"true","masking_description":"","no_masking":"false"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir","arm_group_description":"Treatment Group 1","arm_type":"Experimental"},{"arm_group_label":"Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir","arm_group_description":"Treatment Group 2","arm_type":"Experimental"},{"arm_group_label":"Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir","arm_group_description":"Treatment Group 3","arm_type":"Experimental"},{"arm_group_label":"Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir","arm_group_description":"Treatment Group 4","arm_type":"Experimental"},{"arm_group_label":"Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir","arm_group_description":"Treatment Group 1 (reference arm)","arm_type":"Active Comparator"}],"assignment":"Parallel Assignment","brief_summary":"The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:21:10","criteria":"Inclusion Criteria: - Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening - Treatment experience with antiretroviral therapies (excluding integrase inhibitors) - Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 < 0.1 μM - Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3 Exclusion Criteria: - History (or evidence at Screening) of genotypic resistance to any component of the study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)] - Certain laboratory and electrocardiogram (ECG) values","detailed_description":"Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label. Arms: 5 (4 BMS-663068 treatment groups and 1 reference group) Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"254","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"ae97c207-8691-5d5f-a147-87c18edcb2ba","internal":{"content":null,"contentDigest":"af874a406ace69c594264ffdd98c2052","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening - Treatment experience with antiretroviral therapies (excluding integrase inhibitors) - Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 < 0.1 μM - Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3 Exclusion Criteria: - History (or evidence at Screening) of genotypic resistance to any component of the study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)] - Certain laboratory and electrocardiogram (ECG) values","interventions":[{"arm_group_label":"Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"BMS-663068 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"BMS-663068 800 mg","intervention_type":"Drug"},{"arm_group_label":"Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"BMS-663068 600 mg","intervention_type":"Drug"},{"arm_group_label":"Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"BMS-663068 1200 mg","intervention_type":"Drug"},{"arm_group_label":"Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Raltegravir 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Raltegravir 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Raltegravir 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Raltegravir 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Raltegravir 400 mg","intervention_type":"Drug"},{"arm_group_label":"Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Tenofovir 300 mg","intervention_type":"Drug"},{"arm_group_label":"Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Tenofovir 300 mg","intervention_type":"Drug"},{"arm_group_label":"Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Tenofovir 300 mg","intervention_type":"Drug"},{"arm_group_label":"Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Tenofovir 300 mg","intervention_type":"Drug"},{"arm_group_label":"Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose","intervention_name":"Tenofovir 300 mg","intervention_type":"Drug"},{"arm_group_label":"Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir","intervention_description":"Tablets, Oral, 100 mg, Once daily, 96 weeks","intervention_name":"Ritonavir 100 mg","intervention_type":"Drug"},{"arm_group_label":"Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir","intervention_description":"Capsules, Oral, 300 mg, Once daily, 96 weeks","intervention_name":"Atazanavir 300 mg","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"05/12/2017 00:00:00","links":[],"locations":[{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7786871","CountryDisplay":"United States","Longitude":"-122.4212424","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Córdoba","Latitude":"37.8677249","CountryDisplay":"Spain","Longitude":"-4.7976431","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"14004","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Lima","Latitude":"-12.0471913","CountryDisplay":"Peru","Longitude":"-77.0427055","Name":"GSK Investigational Site","StateDisplay":"Lima","PostalCode":"Lima 11","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Guadalajara","Latitude":"20.6850452","CountryDisplay":"Mexico","Longitude":"-103.342846","Name":"GSK Investigational Site","StateDisplay":"Jalisco","PostalCode":"44280","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Smolensk","Latitude":"54.8127287","CountryDisplay":"Russia","Longitude":"32.0474305","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"214006","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Córdoba","Latitude":"-31.4200833","CountryDisplay":"Argentina","Longitude":"-64.1887761","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"X5000JJS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rosario","Latitude":"-32.9622313","CountryDisplay":"Argentina","Longitude":"-60.6255364","Name":"GSK Investigational Site","StateDisplay":"Santa Fe","PostalCode":"2000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Constanta","Latitude":"44.1598013","CountryDisplay":"Romania","Longitude":"28.6348138","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"900709","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bucharest","Latitude":"44.4267674","CountryDisplay":"Romania","Longitude":"26.1025384","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"021105","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Austin","Latitude":"30.2961708","CountryDisplay":"United States","Longitude":"-97.7389543","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78705","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Philadelphia","Latitude":"39.9583587","CountryDisplay":"United States","Longitude":"-75.1953934","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19104","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Luis Potosi","Latitude":"21.6196107","CountryDisplay":"Mexico","Longitude":"-98.9043841","Name":"GSK Investigational Site","StateDisplay":"San Luis Potosí","PostalCode":"78240","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Observatory, Cape Town","Latitude":"-33.9375585","CountryDisplay":"South Africa","Longitude":"18.4721169","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"7925","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"DF","Latitude":"19.2871869","CountryDisplay":"Mexico","Longitude":"-99.1705253","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"14000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Coral Gables","Latitude":"25.7564662","CountryDisplay":"United States","Longitude":"-80.2711588","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33134","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Berlin","Latitude":"52.4658033","CountryDisplay":"Germany","Longitude":"13.3448464","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"12157","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St. Petersburg","Latitude":"59.9126905","CountryDisplay":"Russia","Longitude":"30.2945611","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"190103","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0320387","CountryDisplay":"Peru","Longitude":"-77.0868865","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"Lima 31","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0452909","CountryDisplay":"Peru","Longitude":"-77.0280218","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"13","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5542151","CountryDisplay":"United States","Longitude":"-81.3454417","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32803","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Saint-Petersburg","Latitude":"59.919045","CountryDisplay":"Russia","Longitude":"30.3766139","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"191167","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Iquitos","Latitude":"-3.7436735","CountryDisplay":"Peru","Longitude":"-73.2516326","Name":"GSK Investigational Site","StateDisplay":"Loreto","PostalCode":"Iqui 01","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bogoto","Latitude":"4.7109886","CountryDisplay":"Colombia","Longitude":"-74.072092","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dundee","Latitude":"-28.1649792","CountryDisplay":"South Africa","Longitude":"30.2343141","Name":"GSK Investigational Site","StateDisplay":"KwaZulu- Natal","PostalCode":"3000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barcelona","Latitude":"41.3899238","CountryDisplay":"Spain","Longitude":"2.1511635","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08036","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Craiova","Latitude":"44.3301785","CountryDisplay":"Romania","Longitude":"23.7948807","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rosario","Latitude":"-32.9442426","CountryDisplay":"Argentina","Longitude":"-60.6505388","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"S2000CXP","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1426EGR","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Longview","Latitude":"32.562483","CountryDisplay":"United States","Longitude":"-94.7070616","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75605","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7097781","CountryDisplay":"United States","Longitude":"-74.0098271","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10008","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bogotá","Latitude":"4.7109886","CountryDisplay":"Colombia","Longitude":"-74.072092","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Hamburg","Latitude":"53.5580847","CountryDisplay":"Germany","Longitude":"10.011979","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20099","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7440941","CountryDisplay":"United States","Longitude":"-84.377861","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30312","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bogota","Latitude":"4.7109886","CountryDisplay":"Colombia","Longitude":"-74.072092","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bonn","Latitude":"50.6980735","CountryDisplay":"Germany","Longitude":"7.0871788","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"53127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Distrito Federal","Latitude":"19.3806445","CountryDisplay":"Mexico","Longitude":"-99.1791765","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03720","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Johannesburg","Latitude":"-26.2041028","CountryDisplay":"South Africa","Longitude":"28.0473051","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"2010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Cincinnati","Latitude":"39.1367664","CountryDisplay":"United States","Longitude":"-84.5022988","Name":"GSK Investigational Site","StateDisplay":"Ohio","PostalCode":"45267-0405","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0501653","CountryDisplay":"Peru","Longitude":"-77.0284697","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Durban","Latitude":"-29.8496216","CountryDisplay":"South Africa","Longitude":"31.0220422","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4001","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1141ACG","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St. Petersburg","Latitude":"59.8404778","CountryDisplay":"Russia","Longitude":"30.5964013","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"196645","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Aguascalientes","Latitude":"21.8685635","CountryDisplay":"Mexico","Longitude":"-102.2991491","Name":"GSK Investigational Site","StateDisplay":"Aguascalientes","PostalCode":"20230","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"München","Latitude":"48.1340355","CountryDisplay":"Germany","Longitude":"11.5571732","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"80336","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7877522","CountryDisplay":"United States","Longitude":"-122.4382307","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94115","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0463731","CountryDisplay":"Peru","Longitude":"-77.042754","Name":"GSK Investigational Site","StateDisplay":"Lima","PostalCode":"1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0778128","CountryDisplay":"Peru","Longitude":"-77.0900708","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"32","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mexico City","Latitude":"19.3813647","CountryDisplay":"Mexico","Longitude":"-99.1680239","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"3100","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Iasi","Latitude":"47.1584549","CountryDisplay":"Romania","Longitude":"27.6014418","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"700116","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ciudad de Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1202ABB","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Badalona","Latitude":"41.474766","CountryDisplay":"Spain","Longitude":"2.2285864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08916","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Zapopan","Latitude":"20.7182797","CountryDisplay":"Mexico","Longitude":"-103.3659489","Name":"GSK Investigational Site","StateDisplay":"Jalisco","PostalCode":"45170","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4731818","CountryDisplay":"Spain","Longitude":"-3.6864121","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28046","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Durham","Latitude":"36.0038131","CountryDisplay":"United States","Longitude":"-78.9387241","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27710","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:42:14","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose","org_study_id":"205889","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":true,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"2","primary_compl_date":"02/18/2013 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of subjects with plasma HIV-1 ribonucleic acid (RNA) < 50 c/mL","outcome_time_frame":"At Week 24","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)","outcome_time_frame":"Up to Week 24","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-011","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"Monotherapy Substudy","outcome_measure":"Changes from monotherapy baseline (Monotherapy Day 1) in log10 HIV ribonucleic acid (RNA) by study day during monotherapy","outcome_time_frame":"Baseline and at Monotherapy Day 7","outcome_safety_issue":null},{"outcome_description":"Monotherapy Substudy","outcome_measure":"Maximum decrease from monotherapy baseline in log10 plasma HIV-1 RNA during monotherapy","outcome_time_frame":"Baseline and at Monotherapy Day 7","outcome_safety_issue":null},{"outcome_description":"Monotherapy Substudy","outcome_measure":"Proportion of subjects with plasma HIV-1 RNA < 50 c/mL at baseline (Combination Therapy Day 1)","outcome_time_frame":"Baseline and at Monotherapy Day 7","outcome_safety_issue":null},{"outcome_description":"Monotherapy Substudy","outcome_measure":"Frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) during monotherapy","outcome_time_frame":"At Monotherapy Day 7","outcome_safety_issue":null},{"outcome_description":"Monotherapy Substudy","outcome_measure":"Changes from monotherapy baseline in CD4+ and CD8+ T-cell counts and percents by study day during monotherapy","outcome_time_frame":"Baseline and at Monotherapy Day 7","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Proportion of subjects with plasma HIV-1 RNA < 50 c/mL","outcome_time_frame":"Week 48","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Frequency of SAEs and discontinuations due to AEs","outcome_time_frame":"Week 48","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Frequency of SAEs and discontinuations due to AE","outcome_time_frame":"Week 96","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Proportion of subjects with plasma HIV-1 RNA < 50 c/mL.","outcome_time_frame":"Week 96","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Changes from baseline in CD4+ T-cell count","outcome_time_frame":"Baseline and Week 24","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Changes from baseline in CD4+ T-cell count.","outcome_time_frame":"Baseline and Week 48","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Changes from baseline in CD4+ T-cell count,","outcome_time_frame":"Baseline and Week 96","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Frequency of newly-emergent genotypic substitutions among subjects with virologic failure","outcome_time_frame":"Week 24","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Frequency of newly-emergent genotypic substitutions among subjects with virologic failure.","outcome_time_frame":"Week 48","outcome_safety_issue":null},{"outcome_description":"Primary Study","outcome_measure":"Frequency of newly-emergent genotypic substitutions among subjects with virologic failure,","outcome_time_frame":"Week 96","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"07/26/2011 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":true}},"pageContext":{"studyId":"205889"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}